APE1: A Multifunctional Protein

Wed, 08/27/2014 - 15:37

AP-endonuclease (APE1/Ref-1) is an essential multifunctional protein involved in the repair of oxidative DNA damage as well as in transcriptional regulation in tumor cells. It functions as an apurinic/apyrimidinic (AP) endodeoxyribonuclease in the DNA base excision repair (BER) pathway of DNA lesions, and may also play a role in the epigenetic regulation of gene expression and the protection from granzymes-mediated cellular repair leading to cell death. APE1 is involved in calcium-dependent down-regulation of parathyroid hormone (PTH) expression by binding to negative calcium response elements (nCaREs).

Melphalan resistance has been considered one of the major obstacles to improve outcomes in multiple myeloma (MM) therapy. A study using Novus’ APE1 antibody, NB100-116, has shown that the acetylation modification of APE1 is involved in melphalan resistance of MM cells and has also shed light on future therapeutic strategies targeting specific APE1 functions by small molecule inhibitors. (1) Another study using the same APE1 antibody describes a unique role of Ape1 in telomere protection, providing a direct link between base excision DNA repair activities and telomere metabolism. (2)

Immunocytochemistry/Immunofluorescence: APE1 Antibody Immunocytochemistry/Immunofluorescence: APE1 Antibody

Resistance to radiotherapy is a key limitation for the treatment of human hepatocellular carcinoma (HCC). A study using Novus’ APE1 antibody, NB100-116, has shown that downregulation of APE1 could enhance sensitivity of human HCC cells to radiotherapy in vitro and in vivo. (3) Radiotherapy is an important treatment for the patients with advanced pancreatic cancer. Emerging studies determined apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) might associate with the resistance of human pancreatic cancer cells to radiotherapy. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro. (4) Abdel-Fatah’s group used Novus’ APE1 antibody, NB100-101 antibody to show that low APE1 expression may have prognostic and predictive significance in ER-positive breast cancers. (5)

  1. PMID: 24400589
  2. PMID: 24127576
  3. PMID: 23418439
  4. PMID: 23268706
  5. PMID: 24381055

Novus Biologicals offers APE1 reagents for your research needs including:

Blog Topics